Lymphoma Program, Winship Cancer Institute, Emory University, 1365 Clifton Road, Atlanta, GA 30322, USA.
Clin Lymphoma Myeloma Leuk. 2010 Dec;10(6):414-23. doi: 10.3816/CLML.2010.n.086.
Our ability to manage patients with non-Hodgkin lymphoma and Hodgkin lymphoma has improved dramatically in the past decade. The survival of patients with the two most frequent lymphomas (ie, diffuse large B-cell lymphoma and follicular lymphoma), have improved significantly with the incorporation of rituximab as a standard treatment regimen. New insights into the biology of lymphomas provided by studying patterns of gene expression have improved our ability to classify these diseases. Identifying the treatments most effective with different patterns of gene expression offers the opportunity to further improve treatment outcomes. We now cure most patients with Hodgkin lymphoma, but the past decade has seen advances in our ability to identify patients who are most likely to be cured with less toxic treatment approaches. Unfortunately, our ability to improve the treatment of patients with peripheral T-cell lymphoma has not kept pace with the management of those suffering from B-cell lymphomas. However, better classification systems, improved understanding of the biology of these disorders, and clinical trials aimed specifically at identifying optimal regimens for patients with aggressive peripheral T-cell lymphomas offer hope to improve treatment results over the next decade.
在过去的十年中，我们治疗非霍奇金淋巴瘤和霍奇金淋巴瘤患者的能力有了显著提高。随着利妥昔单抗作为标准治疗方案的加入，两种最常见的淋巴瘤（即弥漫性大 B 细胞淋巴瘤和滤泡性淋巴瘤）患者的生存率有了显著提高。通过研究基因表达模式对淋巴瘤生物学的新认识，提高了我们对这些疾病进行分类的能力。确定与不同基因表达模式最有效的治疗方法为进一步提高治疗效果提供了机会。我们现在可以治愈大多数霍奇金淋巴瘤患者，但在过去的十年中，我们在识别最有可能通过毒性较小的治疗方法治愈的患者方面取得了进展。不幸的是，我们改善外周 T 细胞淋巴瘤患者治疗的能力并没有跟上治疗 B 细胞淋巴瘤患者的步伐。然而，更好的分类系统、对这些疾病生物学的更好理解以及专门针对确定侵袭性外周 T 细胞淋巴瘤患者最佳治疗方案的临床试验，为未来十年改善治疗结果带来了希望。
